Naringin sensitizes human prostate cancer cells to paclitaxel therapy

Suat Erdogan*, Oguzhan Doganlar, Zeynep B. Doganlar, Kader Turkekul
Department of Medical Biology, School of Medicine, Trakya University, Balkan Campus, Edirne, Turkey

1. Introduction

The main therapeutic option of advanced prostate cancer (PCa) is androgen deprivation therapy with limited clinical outcomes. However, the therapeutic benefit does not last long and most patients develop metastatic castration-resistant prostate cancer (CRPC). After the development of PCa into CRPC, there are several drugs that prolong life, including taxanes such as paclitaxel, docetaxel, and cabazitaxel and new androgen receptor targeting agents like abiraterone acetate and enzalutamide. Microtubule-disrupting agents such as taxanes and vinca alkaloids trigger apoptosis by aberrant mitosis or by subsequent multinucleated G1-like state related to mitotic slippage, depends on cell type and drug schedule. Though taxane chemotherapy is standard first-line therapy for recurrent metastatic CRPC, relapse eventually occurs because of the development of drug resistance. Therefore, there is an essential need for novel effective approaches in the development of novel therapeutic targets and molecular regulatory agents for the treatment of CRPC.

Naringin (4',5,7-trihydroxy flavanone-7-rhamnoglucoside) is a natural glycoside known as bioflavonoid derived from grapefruit and other citrus fruits. Studies have shown that naringin possesses many beneficial pharmacological properties, such as antiinflammatory, antioxidant, and anticancer activities in vivo and in vitro. It has been shown that naringin not only suppresses cancer cell proliferation, but also protects against cisplatin-induced kidney injury through antiapoptotic and antiinflammatory effects. Strategies for combination therapy of cancer with...
chemotherapeutics and natural polyphenols may enhance the potential of the treatment and help to decrease the side effects of standard antitumor therapies.\textsuperscript{11}

The phosphatidylinositol 3’ kinase (PI3K)/Akt signaling pathway is an actively pursued therapeutic target in oncology.\textsuperscript{12} The activation of this axis is emerging as a central feature of epithelial–mesenchymal transition (EMT). EMT has been associated with the invasiveness and the distant metastasis of PCa. Transcription factors such as Twist and Snail are involved in the downregulation of EMT activation.\textsuperscript{13} In this study, we examined the effects of naringin, paclitaxel, or their combination treatment on the cell migration of the PCa cell lines in vitro. Loss or alteration of at least one PTEN (phosphatase and tensin homolog deleted on chromosome 10) allele occurs in 70–80% of primary PCa.\textsuperscript{14} PTEN, a critical tumor and metastasis suppressor gene negatively regulates cell growth, proliferation, migration, and angiogenesis via the PI3K/Akt pathway.\textsuperscript{15, 16} Inhibition of nuclear factor-xB (NF-xB) activity could suppress PCa invasion and metastasis.\textsuperscript{16} Recent studies have demonstrated that naringin inhibits tumor growth via inhibiting NF-xB\textsuperscript{17} and downregulating PI3K/Akt pathway in HeLa cells and human AGS gastric cancer cells,\textsuperscript{13} respectively. Thus, preventing PI3K/Akt signaling and inhibiting NF-xB provide potential targets for tumor therapeutic strategies.

The dietary flavonoid naringin has not been adequately studied as a chemosensitizer in the treatment of PCa. The underlying mechanisms of naringin and in combination with paclitaxel (and vincristine) in the treatment of PCa cells remain to be fully elucidated.

2. Material and methods

2.1. Cell culture and reagents

The human PCa cell lines DU145, PC3, and LNCaP were purchased from the ATCC (Manassas, VA, USA). The cells were seeded in complete medium Dulbecco’s Modified Eagle Medium/Nutrient Mixture F-12K (DMEM/F-12K) medium (DMEM/Ham’s F-12 Mix 50/50; Winsent, Quebec, Canada) supplemented with 10% fetal bovine serum (FBS; Life Technologies, Carlsbad, CA) and maintained at 37°C in a humidified incubator at 5% CO\textsubscript{2}. Paclitaxel (Sindaxel, Actavis, Italy) and naringin (Sigma-Aldrich, St. Louis, MO, USA) were dissolved in 100% dimethyl sulfoxide (DMSO) and stored at −20°C until use. Paclitaxel and naringin were concomitantly administrated to the cultures. The final concentration of DMSO did not exceed 0.1%, and controls received the same volume of vehicle.

2.2. Cell proliferation assay

To quantify the effects of naringin, paclitaxel, or their combination on cell survival, DU145 cells were placed on 96-well plates (10\textsuperscript{4} cells/well) for overnight incubation. The cells were then treated with different concentrations of paclitaxel (0–100 nM) and naringin (0–500 µM) or 5 nM paclitaxel with 150 µM naringin for 72 hour in complete medium. Each treatment was repeated three times. After the incubation period cells were incubated with MTT (Sigma–Aldrich, St. Louis, MO, USA) solution [(1 mg/mL)/well] for 3 hour. The medium was removed, MTT tests were performed, and absorbance at 570 nm was measured using a plate reader (Multiskan GO, Thermo Scientific, Vantaa, Finland).

The efficacy of naringin and paclitaxel or docetaxel (Cayman, MI, USA) combination therapy on cell survival was performed in PC3 and LNCaP lines cells.

2.3. Detection of apoptotic cells

To evaluate the degree of apoptosis, the Tali image-based cytometer apoptosis kit—annexin V Alexa Fluor 488 and propidium iodide—was used according to the manufacturer’s instructions (Invitrogen/Life Technologies, Carlsbad, CA, USA). In brief, DU145 and PC3 were incubated at a density of 2.5 \times 10\textsuperscript{4} in a 6-well plate for 16 hour and then treated with paclitaxel (5 nM), naringin (150 µM), and their combination. The cells were collected 72 hour posttreatment and washed twice with ice-cold phosphate buffer saline (PBS) and were evaluated by Tali image-based cytometer within 30 minutes.

2.4. Analysis of cell cycle

DU145 and PC3 cells were treated with 150 µM of naringin, 5 nM of paclitaxel, 5 nM of vincristine (Kocak Farma, Istanbul, Turkey) or the combinations for 72 hour, harvested, fixed in 70% prechilled ethanol (−20°C) and were set at 4°C overnight. Cells were resuspended in propidium iodide (PI) buffer (50 g/mL PI and 100 µg/mL RNase) and incubated at room temperature for 30 minutes in the dark. Cells were then washed twice with 1 × PBS and subjected to Tali image-based cytometer.

2.5. RNA extraction, cDNA synthesis, and RT-qPCR

Total RNA was purified using RNA purification kit, and RNAs were then subjected to cDNA synthesis using reverse transcription cDNA synthesis kit (Thermo Fisher Scientific, Vilnius, Lithuania). The resultant cDNAs were used for real-time PCR analysis with gene-specific primer pairs. mRNA expression analyses were performed on a Step One Plus Real-Time PCR Systems (Applied Biosystems, Foster City, CA, USA). The PCR cycling conditions included an initial denaturation at 95°C for 5 minutes followed by 36 cycles at 95°C for 15 seconds and 60°C for 60 seconds. The oligonucleotide primers (Table 1) were synthesized by PZR Biotech (Ankara, Turkey). Glycer-aldehyde-3-Phosphate Dehydrogenase (GAPDH) expressions were used as an internal reference, and all reactions were run in triplicate, and performed three times on separate occasions using different RNA.

2.6. Transwell migration assays

To test the effect of naringin and its combination with paclitaxel on cell migration activity, transwell cell invasion assay was performed.\textsuperscript{19} Briefly the bottom chambers (Corning, Kennebunk, ME, USA) were filled with 750 µl of DMEM/F-12K medium with 10% FBS supplemented with or without the agents. Following 22 hour of migration, the DU145 cells were fixed with 4% paraformaldehyde and washed with PBS. After staining with 0.1% crystal violet, pictures of the migrated cells were taken using a microscope with a 10× objective (total magnification 100×).

2.7. Immunoblot analysis

Confluent cells were lysed in RIPA lysis buffer containing protease inhibitor cocktail (Thermo Fisher Scientific, Rockford, IL, USA). After addition of reducing agent, the samples were boiled and then loaded directly to an appropriate well of a NuPAGE® Bis-Tris polyacrylamide gel (10%) immersed in NuPAGE® MOPS SDS running buffer. Separated proteins were transferred to iBlot® Transfer Stack, polyvinylidene difluoride (PVDF) membranes (Life Technologies, Carlsbad, CA, USA). Membranes were incubated with monoclonal NF-xB p50 and β-actin (Novus Biologicals, Littleton, CO, USA), and monoclonal PTEN (Santa Cruz Biotechnology Inc., Santa Cruz, CA, USA) primary antibodies overnight, followed by incubation with
secondary antibodies for 1 hour. The immunoreactive bands were identified using enhanced chemiluminescence (Chemi detection system Mouse-EA, Waltham, MA, USA) by gel imaging system.

2.8. Analysis of drug combinations

The interaction between paclitaxel and naringin was estimated by the isobologram method and the median effect method defined by Chou and Talalay.20 CompuSyn software was used for analysis of combination data in the synergistic studies.

2.9. Statistical analyses

The half maximal inhibitory concentration (IC_{50}) values were calculated using sigmoidal nonlinear regression analyses of cell inhibition as a ratio of the control using GraphPad Prism, version 7.0 (GraphPad Software Inc., La Jolla, CA, USA). Each experiment was performed in triplicate and was repeated at least twice; each data point represents the mean ± standard deviation. Statistical significance was compared between the various treatment groups and the controls using one-way analysis of variance followed by Duncan’s multiple range test for multiple comparisons. A P < 0.05 was considered to indicate a statistically significant difference (SPSS, v19.0, Chicago, IL).

3. Results

3.1. Naringin inhibits cell survival

To assess the sensitivity of DU145 cells to the cytotoxic/cytostatic effects of naringin (3.9 μM–500 μM) and paclitaxel (0.78 nM–100 nM), the cells were seeded into 96-well microplates and incubated with different concentrations of agents as mentioned in Section 2. As shown in Fig. 1, paclitaxel (Fig. 1A–C) and naringin (Fig. 1D–F) reduced the viability of cells in a dose- and time-dependent manner. The IC_{50} values for DU145 cells were 5 nM for paclitaxel and 150 μM for naringin, at 72 hour treatment. Androgen-sensitive prostate cancer LNCaP cells were found to be more resistant to naringin treatment with the IC_{50} value of 260 μM, while PC3 cells were determined to be more sensitive to naringin therapy with an IC_{50} value of 101 μM (data not shown). To reveal possible synergy or additive effects, combinations of 5 nM paclitaxel and 150 μM naringin were administrated to the cells for 72 hour. The combined treatment did significantly strengthen paclitaxel’s cell cytotoxicity effect in DU145 (Fig. 2A), PC3 (Fig. 2C) and LNCaP (Fig. 2E) cells. An intermediate synergism was detected with naringin and paclitaxel in DU145 cells where combination index < 0.72. Dose escalation of naringin (50–800 μM) with constant paclitaxel (5 nM) resulted in a dose-dependent decrease of DU145 cell survival (Fig. 2G).

We also analyzed whether the combination of naringin with another microtubule stabilizer, docetaxel, could show similar effect with paclitaxel. To test this, DU145 (Fig. 2B), PC3 (Fig. 2D) and LNCaP cells (Fig. 2F) were incubated with 5 nM docetaxel, 150 μM naringin, and a combination of the two for 72 hours. Although combination of docetaxel with naringin had a similar effect to paclitaxel in androgen-independent cells, it did not show similar synergy in androgen-sensitive LNCaP cells.

3.2. Naringin induces apoptosis of DU145 and PC3 cells

To assess whether naringin induces apoptosis, image-based cytometric evaluation of DU145 and PC3 cells were examined following exposure to 150 μM naringin and 5 nM paclitaxel or their combination for 72 hour. Annexin V and PI staining demonstrated an increase in the percentage of both cell types undergoing apoptosis (Fig. 3A, B) compared with untreated controls. As shown in Fig. 3A, B, the combined treatment did significantly raise the levels of apoptosis in both cell types when compared with individual treatments.

The apoptosis was also analyzed at the molecular level by RT-qPCR using DU145 cell RNA. Naringin treatment significantly upregulated BAX, BID, caspase 3, and cytochrome c (Cyt-c) expressions while did not change caspase 8, caspase 9, and Bcl-2 mRNA expressions (Fig. 4). Treatment of the cells with paclitaxel induced BAX, caspase 3, and Cyt-c, while it did not alter BID, caspase 8, caspase 9, and Bcl-2 expressions (Fig. 4). The combination of naringin with paclitaxel did upregulate the mRNA expression of caspase 9 (Fig. 4). It is demonstrating that naringin induces intrinsic apoptosis pathway in DU145 cells. However, the combination therapy did markedly downregulate the expression of livin and survivin mRNA (Fig. 4).

3.3. Naringin increases cell cycle arrest in DU145 and PC3 cells

To determine whether naringin regulates the cell cycle, we used image-based cytometry. Treatment with 150 μM naringin significantly increased the number of PC3 and DU145 cells at the G1 phase from 65.5% to 90.3% and 68.5% to 92.0%, respectively (Fig. 5A, B). G1 cell cycle arrest caused by paclitaxel was much less than those seen in naringin treatment. Combination therapy of naringin with paclitaxel significantly enhanced paclitaxel effect in PC3 cells. We also analyzed the effect of naringin with vincristine combination on cell cycle progression of DU145 cells. In contrast to the paclitaxel effect, vincristine did not alter cell cycle and combination with naringin is less effective than those seen in naringin alone (Fig. 5C).
We also examined the expressions of several genes related to cell cycle progress using DU145 cells. Given the essential role of \( p53 \), \( p21 \), and \( p27 \) in growth arrest after DNA damage, we evaluated the influence of naringin on the induction of \( p53 \), \( p21^{\text{Cip1}} \), and \( p27^{\text{Kip1}} \) by performing RT-qPCR. mRNA expression analyses revealed that naringin treatment causes an upregulation of \( p53 \) (2.2 fold), \( p21^{\text{Cip1}} \) (2.5 fold), and \( p27^{\text{Kip1}} \) (1.6 fold) when compared to controls (Fig. 4). A similar effect was observed in paclitaxel treatment. However, induction of \( p53 \), \( p21^{\text{Cip1}} \), and \( p27^{\text{Kip1}} \) expressions was not supported by a combination of naringin and paclitaxel treatment.

**Fig. 1.** Naringin inhibits the proliferation of human DU145 prostate cancer cell viability. Survival rate of the cells treated with different concentrations of paclitaxel (A–C) and naringin (D–F) for indicated hours treatment. Control cells were treated with DMSO-alone. \( *P < 0.05 \) versus untreated. Cell survival was determined following treatment and analyzed by MTT assay. The results were expressed as a percentage of the control value (mean ± SD of three experiments performed in octuplicate wells). SD, standard deviation.
Fig. 2. Efficacy of combination therapy and survival rate in castration-sensitive and -resistant prostate cancer cell lines. DU145 (A, B), PC3 (C, D) and LNCaP (E, F) cells were treated with 5 nM paclitaxel or 5 nM docetaxel, 150 μM naringin or their combinations for 72 h, respectively. Untreated cells were incubated with DMSO-alone. *P < 0.05 versus untreated; **P < 0.05 versus paclitaxel or docetaxel and untreated group. (G) Increased concentrations of naringin with stable dose of paclitaxel (5 nM) significantly enhances the cytotoxic effect of paclitaxel in DU145 cell, treated for 72 h. *P < 0.001 versus untreated, **P < 0.05 versus 50–800, *P < 0.05 versus 50–200, *P < 0.05 versus 50–100, +P < 0.05 versus 50 and 100. Cell survival was determined following therapy, and analyzed by MTT test. The results were expressed as a percentage of the untreated value (mean ± SD of three experiments performed in octuplicate wells). Pac + Nar: paclitaxel and naringin; SD, standard deviation.
3.4. Naringin inhibits cell migration

To investigate whether naringin could inhibit the migration of PCa cells, we performed transwell cell migration assays. The results demonstrated that naringin (150 μM) and paclitaxel (5 nM) markedly decreased DU145 cell migration (Fig. 6A, B). Quantification analysis of transwell assay results indicated that the inhibition rate of naringin, paclitaxel, and their combination were approximately 74%, 87%, and 95%, respectively (Fig. 6B). Combined therapy significantly enhanced the downregulation of Snail, Twist and c-Myc mRNA expressions (Fig. 6C).

3.5. Naringin upregulates PTEN and inhibits NF-κB signaling

PTEN is a major negative regulator of the PI3K/Akt signaling pathway, which regulates proliferation, survival, and growth of PCa. While naringin treatment elevated PTEN protein expression, the combination with paclitaxel significantly increased this effect (Fig. 7A, B). Treatment of cells with naringin markedly inhibited the expression level NF-κB p50 protein (Fig. 7A, C). Paclitaxel treatment similarly inhibited the expression of NF-κB and upregulated PTEN expression. Combination treatment markedly strengthened paclitaxel (Fig. 7A–C).

4. Discussion

Natural flavonoids such as apigenin, luteolin, quercetin, naringin, and epigallocatechin may play a role in the prevention of cancer.7, 15, 18, 21 Investigations have shown that these flavonoids possess inhibition activity on certain cancer growth through diverse mechanisms. Although published data are available regarding anticarcinogenic effects of naringin in different cancer models, there has been only very limited data related to the effect of naringin in androgen-dependent and independent PCa cells and its combination therapy with taxanes. Therefore, we have investigated the properties of naringin in combination with paclitaxel on apoptosis, proliferation, and migration of DU145, PC3, and LNCaP human PCa cells.

Previous reports have shown that naringin weakens the mitotic checkpoint and inhibits cell growth and induces apoptosis through inhibiting NF-κB expression7 in human cervical cancer cells,
This current study demonstrates that naringin treatment with paclitaxel, naringin, and vincristine or their combination for 72 h. Cell cycle distribution was examined using a Tali cell cycle kit. The results showed that naringin treatment caused cell cycle arrest at G1 phase of cells. (A) DU145 and (B) PC3 cells. The cells were treated with 150 μM naringin, 5 nM paclitaxel, 5 nM vincristine or their combination for 72 h. Cell cycle distribution was determined using a Tali cell cycle kit. *p < 0.05 between the untreated, p<0.01 versus paclitaxel or vincristine and naringin, p>0.01 versus paclitaxel. **p < 0.05 between vincristine, paclitaxel, naringin, and control treatment. Our study shows that combination of 150 μM naringin and 5 nM paclitaxel leads to a synergistic inhibitory effect on PCa cell survival through induction of cell death by apoptosis and cell cycle arrest. A comparable effect of naringin was also previously observed in Ehrlich ascites tumor-bearing mice. The authors have reported that naringin exhibits synergistic antitumor activity in combination with the cytotoxic chemotherapeutic drug irinotecan. Moreover, naringin enhances the bioavailability of paclitaxel after oral administration of paclitaxel in rats. Our data suggest that naringin potentially inhibits cell survival, and combination therapy sensitizes androgen-independent cells to paclitaxel as well as docetaxel treatment. Naringin combination therapy also sensitizes androgen-dependent cells to paclitaxel, but this does not apply to docetaxel.

Naringin treatment causes cell survival inhibition in human triple-negative breast cancer cells by targeting β-catenin signaling. Our data show that a significant upregulation in p53, p21<sup>Cip1</sup> and p27<sup>Kip1</sup> occurred during G1-phase arrest in PCa cells treated with naringin, which are consistent with several previous reports. These data led to the hypothesis that naringin has potential as an anticancer compound in PCa cells. In addition, our studies sought to verify whether the combination treatment could synergistically increase cell cycle arrest; image-based cytometer analysis demonstrated that naringin treatment significantly elevates paclitaxel-induced cell cycle arrest in G1 phase. The ability of p21 to stimulate cell cycle inhibition may also depend on its capacity to mediate p53-dependent gene repression, as p21 is both necessary and adequate for p53-dependent repression of genes regulating cell cycle progression. We have shown that, naringin has similar potency to that of paclitaxel in the cell cycle with another microtubule-targeting drug vincristine. The result clearly shows that naringin effectively inhibits the cell cycle in the G1 phase, but the combination with vincristine—actin drugs does not increase its efficacy.

We analyzed whether either naringin alone or in combination with paclitaxel would inhibit DU145 and PC3 cell migration. Our data show that naringin attenuates the metastatic behavior of both cells via downregulating Snail and Twist expressions. Snail and Twist are invasion–associated genes, and they have crucial roles in EMT regulation, invasion, and metastasis of cancer cells. These genes are regulated by NF-κB. Akt and extracellular signal-regulated kinase (ERK) signaling. The tumor suppressor gene PTEN has a negative regulatory role for PI3K/Akt pathway that represses and inhibits the cell cycle in the G1 phase, but the combination with vincristine—actin drugs does not increase its efficacy.
Naringin suppressed cell migration by down-regulating Snail and Twist expressions. (A) Twenty-four hour prestarved DU145 cells were treated with naringin (150 μM), paclitaxel (5 nM), or their combination and being subjected to transwell cell migration assay. (B) The quantitative results for migration data. (C) RT-qPCR mRNA expressions of Snail, Twist and c-Myc in DU145 cells were analyzed 72 h after agent treatments. *P < 0.05 versus untreated/control, **P < 0.05 versus paclitaxel and naringin. Each column represents the mean ± SD. NF-κB, nuclear factor-κB; PTEN, phosphatase and tensin homolog deleted on chromosome 10; Pac + Nar: paclitaxel and naringin; SD, standard deviation.
Pacitaxel and naringin.

PTEN, phosphatase and tensin homolog deleted on chromosome 10; Pacet al. 33 have demonstrated that aberrant methylation and analysis of PTEN and NF-κB expressions, which cause suppression of the migration.31, 32 Phuong et al.33 have shown that naringin sensitizes PCa cells to docetaxel, though ineffective in androgen-dependent PCa cells. These enhanced antiproliferative efficiencies functioned by inducing cell apoptosis, arresting cell cycle, and inhibiting cell migration. The present findings may prove useful in further explorations of the potential application of this combined approach in the treatment of malignant cancer.

5. Conclusions

Taken together, we showed that the bioflavonoid naringin induces apoptosis and cell cycle arrest and reduces the migration ability of PCa cells. The combination of naringin with paclitaxel significantly enhanced the antitumor activity compared with either treatment alone. In addition, naringin sensitizes PCa cells to docetaxel, though ineffective in androgen-dependent PCa cells. These enhanced antiproliferative efficacies functioned by inducing cell apoptosis, arresting cell cycle, and inhibiting cell migration. The present findings may prove useful in further explorations of the potential application of this combined approach in the treatment of malignant cancer.

Conflicts of interest

The authors declare that they have no conflicts of interest concerning this article.

Acknowledgments

This study was funded by the Trakya University Research Project Foundation (Project no: 2016-45), Edirne/Turkey. We would like to thank R. Serttas for his technical assistance.

References

1. Eisenberger MA, Blumenstein BA, Crawford ED, Miller G, McLeod DG, Loehr PJ, et al. Bilateral orchectomy with or without flutamide for metastatic prostate cancer. New Engl J Med 1998;339(15):1036–42.
2. Kapoor A, Wu C, Shayeeghan B, Rybak AP. Contemporary agents in the management of metastatic castration-resistant prostate cancer. Can Urol Assoc J 2016;10(11–12):E414–23.
3. Jordan MA, Wilson L. Microtubules as a target for anticancer drugs. Nature Reviews Cancer 2009;9(4):253–65.
4. Zhu YZ, Liu CF, Nadiminty N, Lou W, Tummlara R, Evans CP, et al. Inhibition of ABCB1 expression overcomes acquired docetaxel resistance in prostate cancer. Mol Cancer Ther 2013;12(9):1829–36.
5. Xianchu L, Lan PZ, Quifang L, Yi L, Xiangcheng R, Wengz H, et al. Naringin protects against lipopolysaccharide-induced cardiac injury in mice. Environ Toxicol Pharmacol 2016;48:1–6.
6. Li H, Yang B, Huang J, Xiang T, Yin X, Wan J, et al. Naringin inhibits growth potential of human triple-negative breast cancer cells by targeting beta-catenin signaling pathway. Toxicol Lett 2013;220(3):219–28.
7. Zeng L, Zhen Y, Chen Y, Zou L, Zhang Y, Hu F, et al. Naringin inhibits growth and induces apoptosis by a mechanism dependent on reduced activation of NFκB/p50/GOX2caspase-1 pathway in HeLa cervical cancer cells. Int J Oncol 2014;45(5):1929–36.
8. Lewinska A, Siwak J, Rzeszutek I, Wnuk M. Diosmin induces genotoxicity and apoptosis in DU145 prostate cancer cell line. Toxicol in Vitro 2015;29(3):417–25.
9. Bharti S, Rani N, Krishnamurthy B, Arya DS. Preclinical evidence for the pharmacological actions of naringin: a review. Planta Med 2014;80(6):437–51.
10. Chitrousou Y, Anay Y, Aroua S, Kebiche M, Fetoui H. Anti-apoptotic and anti-inflammatory effects of naringin on cisplatin-induced renal injury in the rat. Chem Biol Interact 2016;243:1–9.
11. Fantini M, Benvenuto M, Masuelli L, Frajese GV, Tresoldi I, Modesti A, et al. In vitro and in vivo antitumoral effects of combinations of polyphenols, or polyphe- nols and anticancer drugs: perspectives on cancer treatment. Int J Mol Sci 2015;16(5):9236–82.
12. Sever R, Brugge JS. Signal transduction in cancer. Cold Spring Harb Perspect Med 2015;5(4).
13. Smith BN, Odero-Marah VA. The role of Snail in prostate cancer. Cell Adhes Migr 2012;6(5):433–41.
14. Whang YE, Wu XY, Suzuki H, Reiter RE, Tran C, Vessella RL, et al. Inactivation of the tumor suppressor PTEN/MMAC1 in advanced human prostate cancer through loss of expression. Proc Natl Acad Sci USA 1998;95(9):5246–50.
15. Erdogan S, Doganlar O, Doganlar ZB, Seriftas R, Turkekul K, Dibirdik I, et al. The flavonoid apigenin reduces prostate cancer CD44(+) stem cell survival and migration through PI3K/Akt/NF-kappaB signaling. Life sciences 2016;162:77–86.
16. Georgescu MM. PTEN tumor suppressor network in PI3K-Akt pathway control. Genes Cancer 2010;1(12):1170–7.
17. Li Q, Lai Y, Wang C, Xu G, He Z, Shang X, et al. Matrine inhibits the proliferation, invasion and migration of castration-resistant prostate cancer cells through regulation of the NF-kappaB signaling pathway. Oncol Rep 2016;35(1):375–81.
18. Raha S, Yunnam S, Hong GE, Lee HJ, Saralamma VV, Park HS, et al. Naringin induces autophagy-mediated growth inhibition by downregulating the PI3K/Akt/mTOR cascade via activation of MAPK pathways in AGS cancer cells. Int J Oncol 2015;47(3):1061–9.
19. Justus CR, Leffler N, Ruiz-Echevarria M, Yang LV. In vitro cell migration and invasion assays. J Vis Exp. 2014;(88).
20. Chou TC. Drug combination studies and their synergy quantification using the Chou-Talalay method. Cancer Res 2010;70(2):440–6.
21. Lin D, Guan G, Wan J, Zhang X, Li H, Gong X, et al. Luteolin suppresses the metastasis of triple-negative breast cancer by reversing epithelial-to-mesenchymal transition via downregulation of beta-catenin expression. Oncol Rep 2017;37(2):895–902.
22. Zhang YS, Li Y, Wang Y, Sun SY, Jiang T, Li C, et al. Naringin, a natural dietary compound, prevents intestinal tumorigenesis in Apc (Min(+)) mouse model. J Cancer Res Clin Oncol 2016;142(5):913–25.
23. Ramesh E, Alshatwi AW. Naringin induces death receptor and mitochondria-mediated apoptosis in human cervical cancer (SiHa) cells. Food Chem Toxicol 2013;51:97–105.
24. Banjerdpongchai R, Wudistwai B, Khawon P. Induction of human hepatocellular carcinoma HepG2 cell apoptosis by naringin. Asian Pac J Cancer Prev 2016;17(7):3285–94.
25. Knezevic AH, Dick D, Lusicic D, Kopjar N, Orsolic N, Karabeg S, et al. Synergistic effects of irinotecan and flavonoids on Ehrlich ascites tumour-bearing mice. Basic Clin Pharmacol Toxicol 2011;109(5):343–9.
26. Choi JS, Shin SC. Enhanced paclitaxel bioavailability after oral coadministration of paclitaxel produg with naringin to rats. Int J Pharm 2005;292(1-2):149–56.
27. Lee EJ, Moon GS, Choi WS, Kim WJ, Moon SK. Naringin-induced p21/WAF1-mediated G(1)-phase cell cycle arrest via activation of the Ras/Raf/ERK signaling pathway in vascular smooth muscle cells. Food Chem Toxicol 2008;46(12):3800–7.
28. Kim DH, Lee SJ, Lee SB, Park K, Kim WJ, Moon SK. Requirement for Ras/Raf/ERK pathway in naringin-induced G1-cell-cycle arrest via p21/WAF1 expression. Carcinogenesis 2008;29(9):1701–9.
29. Roy S, Singh RP, Agarwal C, Siriwardana S, Sclafani R, Agarwal R. Down-regulation of both p21/Cip1 and p27/Kip1 produces a more aggressive prostate cancer phenotype. Cell Cycle 2008;7(12):1828–35.
30. Ciuffreda L, Falcone I, Incalzi RC, Del Curatolo A, Conciatori F, Matteoni S, et al. PTEN expression and function in adult cancer stem cells and prospects for therapeutic targeting. Adv Biol Regul 2014;56:66–80.
31. Qin Y, Zhao D, Zhou HG, Wang XH, Zhong WL, Chen S, et al. Apigenin inhibits NF-kappaB and snail signaling, EMT and metastasis in human hepatocellular carcinoma. Oncotarget 2016;7(27):41421–31.
32. Shukla S, Gupta S. Suppression of constitutive and tumor necrosis factor alpha-induced nuclear factor (NF)-kappa B activation and induction of apoptosis by apigenin in human prostate carcinoma PC-3 cells: correlation with down-regulation of NF-kappa B-responsive genes. Clin Cancer Res 2004;10(9):3169–78.
33. Phuong NT, Kim SK, Lim SC, Kim HS, Kim TH, Lee KY, et al. Role of PTEN promoter methylation in tamoxifen-resistant breast cancer cells. Breast Cancer Res Treat 2011;130(1):73–83.
34. Fang MZ, Chen DP, Yang CS. Dietary polyphenols may affect DNA methylation. J Nutr 2007;137(1):223s–8s.